58 Journal of Clinical Urology 15(1) Table 1. Patients characteristics following major post-biopsy complication rates. Variables Group 1 (n = 379) Age (years) Life expectancy (years)* BMI (kg/m2) DRE prostatic volume (cm3) US prostatic volume (cm3) Transitional-zone prostatic volume (cm3) PSA (ng/ml) PSA density (ng/ml.cm3) Transitional-zone PSA density (ng/ml.cm3) fPSA/tPSA ratio (n)** Intraprostatic profusion (mm) Post-voiding residual volume (ml) Serum creatinine (mg/ml) 65.5 ± 8.2 16.2 ± 5.3 26.2 ± 4.8 47.6 ± 20.4 50.3 ± 29.7 31.6 ± 25.9 11.4 ± 24.1 0.28 ± 0.7 0.45 ± 0.8 0.14 ± 0.1 (155) 9.6 ± 2.6 57.5 ± 68.1 1.1 ± 0.7 Group 2 (n = 25) p 66.9 ± 9.3 15.4 ± 6.2 28.5 ± 5.2 43.4 ± 17.1 60.4 ± 41.4 32.9 ± 16.0 9.0 ± 6.5 0.19 ± 0.2 0.27 ± 0.1 0.16 ± 0.1 (8) 9.8 ± 2.3 108.1 ± 106.2 1.0 ± 0.2 BMI, body mass index; DRE, digital rectal examination; PSA, prostate-specific antigen; US, ultrasound. Table 2. Possible risk factors for major complications after prostate-biopsy based on anamnesis. Possible risk factors (anamnesis) Group 1 (% of 379) Age (years) ⩾ 60 ⩾ 70 Ethnicity Caucasian (white) Mulatto (brown) African American (black) Other Body mass indices (kg/m2) < 25 25-29 ⩾ 30 Lower urinary tract symptoms IPPS (< 8) IPPS (8-19) IPPS (⩾ 20) 75.3 14.0 9.8 0.8 37.1 42.3 20.6 82.8 10.0 5.4 20.0 50.0 30.0 92.0 4.0 4.0 66.7 29.5 4.2 0.11 77.8 33.5 0.40 0.46 0.04 0.30 0.71 0.88 0.62 0.69 0.50 0.48 0.46 0.02 0.87 Group 2 (% of 25) p 84.0 44.0 0.52 0.28 - 0.69 0.64 (Continued)